At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
DSXSdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With DSXS in Patients With Atopic Dermatitis.
In Brief
A Phase 2 clinical trial evaluating DSXS for Dermatitis, Atopic. Completed, enrolled 24 participants across 1 site.
Detailed Summary
this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
First PostedNov 2015
Primary CompletionFeb 2017
Study CompletionAug 2017
TodayJul 2026
First PostedNov 3, 2015
Enrollment StartAug 28, 2015
Primary CompletionFeb 22, 2017
Study CompletionAug 25, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.7 years ago
Interventions
DSXSdrug
Active treatment